Business Context and Reporting Period
Company: NeuroSense Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: May 23, 2024
Reporting Period: Month of May 2024
This filing serves as a notice to shareholders regarding the scheduling of the Company's Annual General Meeting (AGM). The meeting is set for June 27, 2024, at 11:00 a.m. Israel time, to be held at the Company's principal executive offices in Herzliya, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice and does not contain financial statements or performance data.
Material Changes
No material financial changes or operational updates versus the prior comparable period are disclosed in this filing.
Guidance, Outlook, and Management Commentary
Management Action: The Company has scheduled its Annual General Meeting of Shareholders for June 27, 2024.
Exhibit: A Notice of the Annual General Meeting is furnished as Exhibit 99.1.
Regulatory Note: This report is incorporated by reference into the registrant's Registration Statements on Form S-8 (File No. 333-262480) and Form F-3 (File No. 333-269306).
Key Facts for Investor Verification
- Verify the date and time of the Annual General Meeting: June 27, 2024, at 11:00 a.m. Israel time.
- Confirm the meeting location: 11 HaMenofim Street, Building B, Herzliya, Israel.
- Review Exhibit 99.1 for the full Notice of the Annual General Meeting.
- Note that this filing contains no financial performance data; investors should refer to the most recent Form 20-F for financial metrics.